5.
Dang C, Harrington K, Lim Y, Ames D, Hassenstab J, Laws S
. Relationship Between Amyloid-β Positivity and Progression to Mild Cognitive Impairment or Dementia over 8 Years in Cognitively Normal Older Adults. J Alzheimers Dis. 2018; 65(4):1313-1325.
DOI: 10.3233/JAD-180507.
View
6.
Brecht W, Harris F, Chang S, Tesseur I, Yu G, Xu Q
. Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. J Neurosci. 2004; 24(10):2527-34.
PMC: 6729489.
DOI: 10.1523/JNEUROSCI.4315-03.2004.
View
7.
Filon J, Intorcia A, Sue L, Arreola E, Wilson J, Davis K
. Gender Differences in Alzheimer Disease: Brain Atrophy, Histopathology Burden, and Cognition. J Neuropathol Exp Neurol. 2016; 75(8):748-754.
PMC: 7299435.
DOI: 10.1093/jnen/nlw047.
View
8.
Cosker K, Mallach A, Limaye J, Piers T, Staddon J, Neame S
. Microglial signalling pathway deficits associated with the patient derived R47H TREM2 variants linked to AD indicate inability to activate inflammasome. Sci Rep. 2021; 11(1):13316.
PMC: 8233372.
DOI: 10.1038/s41598-021-91207-1.
View
9.
La Joie R, Visani A, Lesman-Segev O, Baker S, Edwards L, Iaccarino L
. Association of and Clinical Variability in Alzheimer Disease With the Pattern of Tau- and Amyloid-PET. Neurology. 2020; 96(5):e650-e661.
PMC: 7884991.
DOI: 10.1212/WNL.0000000000011270.
View
10.
Braak H, Braak E
. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991; 82(4):239-59.
DOI: 10.1007/BF00308809.
View
11.
Ulland T, Colonna M
. TREM2 - a key player in microglial biology and Alzheimer disease. Nat Rev Neurol. 2018; 14(11):667-675.
DOI: 10.1038/s41582-018-0072-1.
View
12.
Klunk W, Koeppe R, Price J, Benzinger T, Devous Sr M, Jagust W
. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2014; 11(1):1-15.e1-4.
PMC: 4300247.
DOI: 10.1016/j.jalz.2014.07.003.
View
13.
Sirkis D, Bonham L, Aparicio R, Geier E, Ramos E, Wang Q
. Rare TREM2 variants associated with Alzheimer's disease display reduced cell surface expression. Acta Neuropathol Commun. 2016; 4(1):98.
PMC: 5010724.
DOI: 10.1186/s40478-016-0367-7.
View
14.
Young C, Johns E, Kennedy G, Belloy M, Insel P, Greicius M
. APOE effects on regional tau in preclinical Alzheimer's disease. Mol Neurodegener. 2023; 18(1):1.
PMC: 9811772.
DOI: 10.1186/s13024-022-00590-4.
View
15.
Wang Y, Cella M, Mallinson K, Ulrich J, Young K, Robinette M
. TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. Cell. 2015; 160(6):1061-71.
PMC: 4477963.
DOI: 10.1016/j.cell.2015.01.049.
View
16.
Shi Y, Yamada K, Liddelow S, Smith S, Zhao L, Luo W
. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature. 2017; 549(7673):523-527.
PMC: 5641217.
DOI: 10.1038/nature24016.
View
17.
Stancu I, Cremers N, Vanrusselt H, Couturier J, Vanoosthuyse A, Kessels S
. Aggregated Tau activates NLRP3-ASC inflammasome exacerbating exogenously seeded and non-exogenously seeded Tau pathology in vivo. Acta Neuropathol. 2019; 137(4):599-617.
PMC: 6426830.
DOI: 10.1007/s00401-018-01957-y.
View
18.
Carmona S, Zahs K, Wu E, Dakin K, Bras J, Guerreiro R
. The role of TREM2 in Alzheimer's disease and other neurodegenerative disorders. Lancet Neurol. 2018; 17(8):721-730.
DOI: 10.1016/S1474-4422(18)30232-1.
View
19.
Zhu B, Liu Y, Hwang S, Archuleta K, Huang H, Campos A
. Trem2 deletion enhances tau dispersion and pathology through microglia exosomes. Mol Neurodegener. 2022; 17(1):58.
PMC: 9438095.
DOI: 10.1186/s13024-022-00562-8.
View